PARI : eFlow delivers Alnylam RNAi Therapeutic in Phase II study

APRIL 17, 2008 – An optimized PARI eFlow platform nebulizer will be delivering Alnylam’s ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients. ALN-RSV01 is a RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading cause of pediatric hospitalization in the U.S. and a prevalent infection in immune-compromised adults. RSV currently does not have a viable treatment option.

“The progression into Phase II clinical trials with Alnylam’s therapeutic is significant as it is the first RNAi program in clinical trials using inhalation... PARI Pharma's Press Release -